ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with the 2-drug regimen Dovato (dolutegravir plus lamivudine) in virally suppressed patients switching from a TAF-containing, 3-drug regimen

This is an archived press release which may not reflect current medical knowledge and should not be used as a source of information on the present label, safety data or efficacy data for ViiV Healthcare products and/or their uses. Please refer to your nationally approved label or summary of product characteristics for up-to-date product information.